Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
In a November 1995 experiment run in Jim Allison's lab, every mouse given a CTLA-4 blocking antibody was cured of tumors while the control mice died.
“Every mouse that got the antibody was completely cured, no tumors at all, while the entire control group grew sicker and died.”
0:07:18 · Alex Kesin · CTLA-4 experiment · 1995
Bristol Myers Squibb's Peter Lindsley's group filed on CTLA-4 in June 1991, about three years before Jim Allison's lab worked out what it did.
“Pierre Lindsley's group at BMS got there in June of 1991, three years ahead of Allison.”
0:08:40 · Alex Kesin · CTLA-4 patents · 1991
The FDA approved Yervoy (ipilimumab) in March 2011 as the first cancer drug that worked purely by releasing the immune system's brake.
“Yervoy was approved in March 2011. It was a landmark.”
0:11:11 · Matthew Pech · Yervoy approval · 2011
Tasuku Honjo's lab discovered the PD-1 gene in 1991, naming it for programmed cell death.
“In 1991, a Japanese researcher named Tasuku Honjo and his lab discovered a gene they named PD-1, which stands for Programmed Death 1.”
0:12:03 · Alex Kesin · PD-1 discovery · 1991
In 1997 Lieping Chen's team found that many cancer tissues overexpressed PD-L1 while normal tissues barely expressed it.
“in 1997, they discovered that a ton of cancer tissues overexpressed PD-L1, while normal, healthy tissues barely seemed to express it at all.”
0:14:59 · Matthew Pech · PD-L1 discovery · 1997
Organon, the Dutch company where pembrolizumab began, was a subsidiary of the paint maker Akzo Nobel.
“To make things even weirder, Organon was a subsidiary of another company called Axo Nobel,”
0:16:51 · Alex Kesin · Organon ownership
In 2005 Organon opened a new 30-person research site in Cambridge, Massachusetts to build a biologics and autoimmunity pipeline.
“In 2005, they plant a flag right in Cambridge, Massachusetts and launch a brand new 30-person research site.”
0:18:01 · Speaker 3 · Organon research site · 2005
Schering-Plough acquired Organon in 2007 for $14.4 billion.
“in 2007, Sharing Plow acquires Organon for $14.4 billion in order to enhance their portfolio of late-stage clinical assets.”
0:29:59 · Alex Kesin · Schering-Plough acquisition · 2007
Merck and Schering-Plough agreed to a $41 billion merger in 2009, structured as a reverse merger with Schering-Plough as the legal acquirer.
“It's 2009. Merck and Shering Plough agree to a massive $41 billion mega merger.”
0:31:21 · Matthew Pech · Merck merger · 2009
Merck began Keynote 001, a 30-patient phase one pembrolizumab study in melanoma, in 2011.
“In 2011, they initiated a small 30-patient phase one study focused on melanoma. They call it Keynote 001.”
0:45:05 · Matthew Pech · Keynote 001 · 2011
Worldwide sales of Merck's asthma drug Singulair fell 75% year over year by the first quarter of 2013 after its patent expired.
“By the first quarter of 2013, worldwide sales had collapsed 75 % year over year.”
0:46:13 · Speaker 3 · Singulair patent cliff · 2013
Under Roger Perlmutter, more than half of Merck's drug development budget was redirected to pembrolizumab, funding over 700 clinical trials.
“ultimately more than half of Merck's entire drug development budget gets redirected towards pembrolizumab, ultimately fueling over 700 clinical trials across dozens of cancer types.”
0:51:09 · Matthew Pech · Merck R&D budget · 2013
Merck received FDA Breakthrough Therapy Designation for pembrolizumab in January 2013, which BMS's nivolumab did not have.
“Because of that early melanoma data with Pembrolizumab, Merck applied for and got the breakthrough designation in January 2013, a few months before Perimuter arrived on site.”
0:55:58 · Matthew Pech · Breakthrough designation · 2013
The FDA granted accelerated approval to pembrolizumab (Keytruda) for advanced melanoma on September 4, 2014.
“On September 4th of 2014, the FDA grants accelerated approval to Pembrolizumab, Keytruda for advanced melanoma.”
0:58:23 · Alex Kesin · Keytruda approval · 2014
In BMS's early nivolumab data, none of 17 PD-L1-negative patients responded, while nine of 25 PD-L1-positive patients did.
“Out of 42 patients they evaluated, zero of the 17 PD-L1 negative patients responded, but nine out of the 25 PD-L1 positive patients did.”
1:03:43 · Alex Kesin · PD-L1 signal · 2012
Merck's Keynote 001 data showed about a 45% response rate in patients with PD-L1 expression above 50% versus about 10% in those below 1%.
“They discovered that patients with expression above 50 % had a roughly 45 % response rate, while patients below 1 % PD-L1 responded at only about a 10 % rate.”
1:06:01 · Speaker 3 · PD-L1 biomarker
BMS's all-comers first-line lung cancer trial Checkmate 26 had a hazard ratio of 1.02 and failed, while Merck's enriched Keynote 24 trial succeeded.
“BMS's all comers trial, Checkmate 26, produced a hazard ratio of 1.02. It showed absolutely zero benefit and completely failed.”
1:08:18 · Alex Kesin · Lung cancer trials
A 41-patient Johns Hopkins trial tested Keytruda in patients with and without DNA repair-deficient tumors, finding response rates of 40 to 71% in the deficient group.
“set up their own small 41-patient trial to test Keytruda in both patients who had DNA repair-deficient tumors and in patients with normal tumors.”
1:14:43 · Matthew Pech · MSI-H trial
In 2017 the FDA approved pembrolizumab for any solid tumor with a specific DNA repair defect, the first approval based on a biomarker regardless of tumor origin.
“And in 2017, the FDA approved pembrolizumab for the treatment of any solid tumor with the specific DNA repair defect, regardless of where in the body the cancer originated.”
1:16:10 · Alex Kesin · Tissue-agnostic approval · 2017
In 2018 Merck published Keynote 189, which combined Keytruda with chemotherapy in lung cancer patients regardless of PD-L1 status.
“In 2018, Merck publishes the results of their combination trial, Keynote 189. They gave Keytruda and standard of care chemotherapy to all comers”
1:18:24 · Matthew Pech · Keynote 189 · 2018
By 2018 there were over 160 PD-1 and PD-L1 drugs in development worldwide.
“There were suddenly over 160 different PD-1 and PD-L1 drugs in the pipeline worldwide.”
1:25:29 · Alex Kesin · PD-1 gold rush · 2018
Gilead spent nearly $5 billion acquiring Forty Seven Inc. for its CD47 drug magrolimab, and the program was later scrapped.
“Gilead spent nearly $5 billion acquiring 47 Inc. to get their flagship CD47 drug, Migrolumab.”
1:29:11 · Alex Kesin · CD47 failure
After Keynote 24, five-year overall survival for PD-L1-high lung cancer patients on first-line Keytruda was 30%, versus 16% on chemotherapy.
“after Keynote 24, first-line Keytruda monotherapy in PD-L1 high patients, the five-year overall survival rate is 30 % compared to just 16 % on chemo.”
1:34:46 · Alex Kesin · Lung cancer survival
In the Keynote 6 melanoma trial, 34% of Keytruda patients were alive after 10 years of follow-up.
“In Keynote 6, 34 % of Keytruda patients are alive after 10-year follow-up.”
1:35:42 · Matthew Pech · Melanoma survival
MRC Technology, which helped humanize pembrolizumab, sold part of its royalty rights to a private equity fund for about $150 million before Keytruda's sales took off.
“they decided to sell a chunk of their royalty rights off to a private equity fund for about $150 million.”
1:42:17 · Matthew Pech · MRC royalty sale
Keytruda's original patents begin expiring in 2028, with eight pembrolizumab biosimilars said to be in development.
“The original patents for Keytruda begin expiring in 2028, and there are already eight different Pembro biosimilars in development ready to jump in when it finally does.”
1:44:14 · Alex Kesin · Patent expiry · 2028
Merck launched Keytruda Qlex, a subcutaneous version of Keytruda, in late 2025.
“In late 2025 last year, Merck launched Keytruda Qlex, which is a subcutaneous version of the drug.”
1:45:35 · Alex Kesin · Keytruda Qlex · 2025
Summit Therapeutics and Akeso's PD-1/VEGF bispecific antibody ivonescimab produced strong phase three results in China, beating Keytruda plus chemotherapy on progression-free survival in a lung cancer trial.
“They developed this PD-1 -X-VEGF bispecific antibody called Ivaneskimab, and it recently produced incredibly strong phase three results in China.”
1:51:39 · Alex Kesin · Ivonescimab
Former U.S. president Jimmy Carter disclosed in August 2015, at age 90, that he had metastatic melanoma that had spread to his brain, and was treated with radiation and pembrolizumab.
“In August 2015, former president Jimmy Carter disclosed that he had metastatic melanoma that had spread to his brain. He was 90 years old at the time.”
2:05:52 · Matthew Pech · Jimmy Carter case · 2015